The medicinal use of Chinese Herbal Medicine (CHM) dates back more than 3,000 years; today it remains an integral part of Traditional Chinese and East Asian Medicine, accounting for 90% of China’s medicinal treatments. Each year about 1.28 billion patients seek various forms of CHM, including acupuncture, massage and Qigong therapy. As herbal medicine continues to grow in the East, its reach influences Western countries, and has become part of a multibillion-dollar market.
China Health Resource, Inc. (OTCBB: CHRI) devotes its operations to the development of traditional Chinese herbal medicine, focusing on a unique Chinese herbal medicine used to treat pain and various afflictions. Dahurian Angelica Root (DAR) is believed do cure diseases such as high-blood pressure, cancer and more.
The description and classification of each medicinal herb is dire for the continuation of CHM. An herbal pharmacopoeia details medicinal substances, describing physical characteristics and applications. China’s pharmacopoeia contains more than 10,000 entries, while the U.S. covers roughly 400. To further its own development and studies of DAR, China Health Resource has established a relationship with Chengdu University of Traditional Chinese Medicine and the Sichuan Provincial Chinese Medicine Research Institute.
China Health Resource cites that DAR’s applications are expanding from the medical field, and are now used for cosmetics and chemistry purposes. According to the company, the international market share of herbal medicine is up to 27 billion U.S. dollars each year, and continues to grow. China Health Resource is focused on expanding the global market of DAR, and making a dominant presence in the industry.
Let us hear your thoughts: China Health Resource, Inc. Message Board